Rheumatology Advisor

http://RheumatologyAdvisor.com provides healthcare specialists with a valuable resource filled with practical information on rheumatology to aid in their clinical decision-making. Our goal is to support rheumatology professionals by offering detailed and relevant clinical and medication information that aligns with the latest care principles, enabling clinicians to enhance patient outcomes effectively.

Trade/B2B

English

Newsletter (Digital), Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#542767

United States

#213244

Health/Health

#4072

Traffic sources

Monthly visitors

Articles

Subcutaneous Infliximab Outperforms Combination Therapy for IBD

5 days ago | rheumatologyadvisor.com | Jessica Nye

Immunogenicity is more prevalent among individuals who receive subcutaneous (SC) infliximab vs intravenous (IV) infliximab with an immunomodulator combined, according to study results published in Clinical Gastroenterology and Hepatology. Data about whether IV combinatorial or IV infliximab monotherapy is associated with decreased risk for immunogenicity have been conflicting. In addition, an SC infliximab formulation is now available.
Comparable Survival Found With ICI Treatment in mNSCLC With vs Without RA

1 week ago | rheumatologyadvisor.com | Hibah Khaja

Among patients with metastatic nonsmall cell lung cancer (mNSCLC) receiving immune checkpoint inhibitors, those with vs without coexisting rheumatoid arthritis (RA) experience similar overall survival outcomes, according to study results published in ACR Open Rheumatology. These findings suggest that RA, despite its autoimmune nature and associated immunosuppressive treatments, should not be considered a contraindication to ICI therapy among patients with advanced lung cancer.
Mental Distress Rates Increase After Texas Abortion Ban

1 week ago | rheumatologyadvisor.com | Jessica Nye

Since the implementation of the Texas Heartbeat Act Senate Bill 8 (SB8) was in 2021, mental distress has increased, particularly among younger individuals, according to findings published in JAMA Network Open. SB8 bans abortion after detection of embryonic cardiac activity, effectively banning the procedure altogether. This made Texas the most restrictive state in the United States.
Navigating the Changing Landscape of LGBTQ+ Health Care: Q&A With Carlos Gutiérrez, EdD, MMS, PA-C

1 week ago | rheumatologyadvisor.com | Nikki Kean

The Clinical Advisor is celebrating PRIDE Month. To gauge how the changing landscape surrounding diversity, equity, and inclusion (DEI) policy is affecting LGBTQ+ patients, we spoke with Carlos Gutiérrez, EdD, MMS, PA-C. Dr Gutiérrez is an associate professor and vice chair of Student Success for the Department of Physician Assistant Studies at the School of Health and Rehabilitation Sciences, University of Pittsburgh. He is also president of the Arizona State Association of Physician Assistants.
Myocardial Fibrosis and Multiorgan Pathology May Drive Sudden Death in SSc

1 week ago | rheumatologyadvisor.com | Hibah Khaja

Sudden cardiac death and multiorgan pathology may be more closely linked to systemic sclerosis (SSc) than previously recognized, with myocardial fibrosis occurring independently of traditional causes in the majority of cases, according to study findings published in Seminars in Arthritis & Rheumatism.
FDA Drug Approval Decisions Expected in July 2025

1 week ago | rheumatologyadvisor.com | Diana Ernst

The Prescription Drug User Fee Act (PDUFA) date refers to the deadline set by the US Food and Drug Administration (FDA) for reviewing a New Drug Application (NDA) or Biologics License Application (BLA) and making a final decision on marketing approval. The typical period for review is 10 months after the drug application has been accepted by the Agency. For drugs that have Priority Review, the review period is reduced to 6 months from the time of application acceptance.
May 2025 Recap: Drug Pipeline Updates

1 week ago | rheumatologyadvisor.com | Steve Duffy

The table below is a review of notable updates that occurred in May 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage. DrugPharmacologic ClassProposed IndicationStatusCardiovascular DiseaseAficamten (Cytokinetics)Cardiac myosin inhibitorTreatment of obstructive hypertrophic cardiomyopathy.
CTD-ILD Burden Highest Among Women and Older Adults

2 weeks ago | rheumatologyadvisor.com | Hibah Khaja

Approximately 116,000 to 118,000 adults in the United States may be living with interstitial lung disease (ILD) associated with connective tissue diseases (CTD), with the highest incidence and prevalence rates observed among older individuals and women, according to study results presented at the European Alliance of Associations for Rheumatology (EULAR) Congress 2025, held from June 11 to 14 in Barcelona, Spain.
Rituximab Reduces Immune Response to Herpes Zoster Vaccine in ARDs

2 weeks ago | rheumatologyadvisor.com | Hibah Khaja

The use of rituximab (RTX) significantly diminishes the humoral immune response to the recombinant herpes zoster vaccine (RZV) among patients with autoimmune rheumatic diseases (ARDs), according to study results presented at the European Alliance of Associations for Rheumatology (EULAR) Congress 2025, held from June 11 to 14 in Barcelona, Spain. Rituximab, a B cell-depleting therapy commonly used to treat ARDs, has been associated with increased infection risk.
Bimekizumab Improves Joint and Skin Outcomes in Psoriatic Arthritis Over 3 Years

2 weeks ago | rheumatologyadvisor.com | Hibah Khaja

Treatment with bimekizumab (BKZ), a monoclonal antibody targeting interleukin (IL)-17A and IL-17F, led to sustained improvements in joint and skin outcomes over 3-years among biologic-naïve patients with active psoriatic arthritis (PsA), according to study results presented at the European Alliance of Associations for Rheumatology (EULAR) Congress 2025, held from June 11 to 14 in Barcelona, Spain.